Approval · Notice of Compliance 22363 · 2019
KEYTRUDA: Notice of Compliance 22363
Issued July 4, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22363
- Date
- July 4, 2019
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: keytruda, in combination with carboplatin and either peclitaxel or nab-paclitaxel is indicated for the treatment of metastatic squamous nsclc in adults with no prior systemicc chemotherapy treatment for metastatic nsclc
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KEYTRUDA | Not yet assigned | — |
Medicinal ingredients
- PEMBROLIZUMAB 50 MG per VIAL
- PEMBROLIZUMAB 25 MG per ML